Palantir's growth potential and moat in data capture, analysis, and modeling are evident, but share-based compensation remains a concern. Palantir's free cash flow grew 70.7% YoY, driven by new ...
LifeMD is trading at a low multiple to sales of 1.08x even as the telehealth company generates material revenue growth. The preferreds are trading a tighter discount to their $25 per share liquidation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback